股票代码：300759.SZ 股票代码：3759.HK 2024 三 季 报 说 明 会 2024年10月 前瞻性陈述 本演示文稿呈现的文件、观点和材料（以下简称"文件"）由康龙化成(北京)新药技术股份有限公司(以下简称"公司")编制，供本公司在演示文稿中用于报告使用，不构成对本公司有关证券的推荐。您完 全理解该文件是在保密的基础上提供的，并遵守以下规定。本文件内容未经任何司法管辖区的任何监管机构审核。在某些司法管辖区，本文件的分发可能受到法律的限制，持有本文件的收件人应告 知自己并遵守这些限制。通过访问本文件，即表示您同意(i)您已阅读并同意遵守本文件通知和免责声明的内容，以及(ii)对在本文件中披露的信息绝对保密。 本文件未经独立核实，不构成任何投资决策的依据。不构成要约或邀请,也不构成在任何司法管辖区域内要求认购或购买任何证券的要约邀请（报价）,在根据该司法管辖区的证券法进行注册或取得资 格之前，征集或出售都将是非法的，或者不符合该司法管辖区的法律法规，并且文件中的任何内容均不构成任何投资决策、合同或承诺的基础。本文件不包含任何可能导致被视为(1)广告的信息或材 料，包含在《证券及期货条例》(香港法律第 ...

康龙化成：第三季度净利润3.08亿元 同比下降12.62% 财联社10月29日电，康龙化成发布2024年第三季 度报告，前三季度实现营业收入88.17亿元，同比增长3%；归属于上市公司股东的净利润14.22亿元，同 比增长24.82%。 其中，第三季度实现营业收入32.13亿元，同比增长10.02%；归属于上市公司股东的净利润3.08亿元， 同比下降12.62%。 查看公告原文 ...

Financial Performance - Revenue for Q3 2024 reached 3,212,811,697.13 yuan, a year-on-year increase of 10.02%[3] - Net profit attributable to shareholders in Q3 2024 was 308,396,080.13 yuan, a year-on-year decrease of 12.62%[3] - Total assets as of the end of Q3 2024 were 23,570,041,501.34 yuan, a year-on-year decrease of 10.98%[3] - Total operating revenue for the current period is 8,817,275,052.00 yuan, an increase from 8,560,256,911.27 yuan in the previous period[24] - Operating profit for the current period is 1,627,236,356.80 yuan, up from 1,328,483,021.07 yuan in the previous period[24] - Net profit attributable to the parent company's shareholders is 1,421,799,112.63 yuan, compared to 1,139,038,016.10 yuan in the previous period[25] - Basic earnings per share (EPS) for the current period is 0.8028, up from 0.6430 in the previous period[25] - Total comprehensive income for the current period is 1,430,086,645.22 yuan, compared to 1,107,456,956.68 yuan in the previous period[25] - Net profit for the current period is 1,369,206,716.49 yuan, compared to 1,134,523,142.41 yuan in the previous period[25] - Total comprehensive income attributable to the parent company's shareholders is 1,478,341,755.57 yuan, up from 1,112,499,103.26 yuan in the previous period[25] Revenue Breakdown by Service and Region - Laboratory services revenue for the first three quarters of 2024 was 5,218,670,210.75 yuan, a year-on-year increase of 2.95%[4] - CMC (small molecule CDMO) services revenue for the first three quarters of 2024 was 1,976,627,679.48 yuan, a year-on-year increase of 3.29%[4] - Revenue from North American clients in the first three quarters of 2024 was 573,067.48 million yuan, a year-on-year increase of 4.29%[5] - Revenue from Chinese clients in the first three quarters of 2024 was 132,879.79 million yuan, a year-on-year decrease of 12.14%[5] - Revenue from European clients (including the UK) in the first three quarters of 2024 was 152,731.20 million yuan, a year-on-year increase of 15.74%[5] - The company's overseas laboratories and factories saw a revenue decline of 1.34% in the first three quarters of 2024, accounting for 12.78% of total revenue[5] New Orders and Growth - New orders in the first three quarters of 2024 increased by over 18% year-on-year, with CMC services new orders growing by over 30%[6] Cash Flow and Financial Position - Cash and cash equivalents decreased by RMB 3.86 billion, a 66.19% drop compared to the beginning of the year[10] - Prepaid expenses increased by RMB 7.76 million, a 43.59% rise due to higher prepayments for raw material purchases[10] - Other receivables grew by RMB 51.75 million, a 45.74% increase mainly due to higher tax refund subsidies[10] - Deferred tax assets increased by RMB 54.30 million, a 35.44% rise due to higher deferred tax assets related to deductible losses[10] - Investment income surged by RMB 567.42 million, a 1,158.41% increase due to gains from the disposal of non-current financial assets and convertible bond repurchases[10] - Fair value change losses decreased by RMB 62.32 million, a 155.03% drop due to reduced gains from biological assets and derivative financial instruments[10] - Asset disposal losses increased by RMB 23.92 million, a 9,732.09% rise due to higher non-current asset disposal losses[11] - Non-operating income decreased by RMB 2.19 million, a 64.56% drop due to reduced government subsidies[11] - Income tax expenses increased by RMB 66.25 million, a 35.54% rise due to higher profit[11] - Total assets decreased to 23.57 billion yuan from 26.48 billion yuan at the beginning of the period[21][22] - Current assets decreased to 7.10 billion yuan from 10.87 billion yuan at the beginning of the period[21] - Non-current assets increased to 16.47 billion yuan from 15.60 billion yuan at the beginning of the period[21] - Total liabilities decreased to 9.54 billion yuan from 13.24 billion yuan at the beginning of the period[22] - Current liabilities increased to 4.16 billion yuan from 3.65 billion yuan at the beginning of the period[22] - Non-current liabilities decreased to 5.39 billion yuan from 9.58 billion yuan at the beginning of the period[22] - Owner's equity increased to 14.03 billion yuan from 13.24 billion yuan at the beginning of the period[22] - Cash and cash equivalents decreased to 2.00 billion yuan from 5.92 billion yuan at the beginning of the period[21] - Accounts receivable increased to 2.27 billion yuan from 2.24 billion yuan at the beginning of the period[21] - Inventory increased to 1.20 billion yuan from 1.01 billion yuan at the beginning of the period[21] - Sales of goods and services received cash of 8,940,386,810.41 yuan, an increase from 8,345,874,274.78 yuan in the previous period[26] - Cash received from tax refunds was 417,480,501.78 yuan, up from 384,922,168.66 yuan in the previous period[26] - Total cash inflow from operating activities was 9,481,564,856.83 yuan, compared to 8,954,356,730.64 yuan in the previous period[26] - Cash paid for goods and services was 1,740,077,789.56 yuan, an increase from 1,602,776,669.59 yuan in the previous period[26] - Cash paid to employees and for employee benefits was 4,309,827,312.87 yuan, up from 3,912,340,413.31 yuan in the previous period[26] - Net cash flow from operating activities was 1,770,502,528.88 yuan, a decrease from 2,029,402,975.72 yuan in the previous period[26] - Net cash flow from investing activities was -897,439,031.21 yuan, an improvement from -1,807,866,341.75 yuan in the previous period[26] - Net cash flow from financing activities was -4,785,948,104.84 yuan, a significant decrease from 431,485,182.20 yuan in the previous period[27] - The net increase in cash and cash equivalents was -3,857,571,108.40 yuan, compared to 663,129,877.44 yuan in the previous period[27] - The ending balance of cash and cash equivalents was 1,931,543,560.63 yuan, down from 2,022,842,617.58 yuan in the previous period[27] Shareholder and Investment Information - The top shareholder, HKSCC NOMINEES LIMITED, holds 16.87% of the shares, totaling 301,501,968 shares[12] - China Bank holds 25,892,311 shares, accounting for 1.45% of the total shares[14] - Industrial and Commercial Bank of China holds 13,655,593 shares, accounting for 0.76% of the total shares[14] - The company acquired approximately 78.5% equity of Shanghai Jiyin Intelligent Technology Co., Ltd. for RMB 43 million[17] - The company completed the first tranche of equity transfer payment and obtained control of Shanghai Jiyin in July 2024[17] - All first batch of HKD 300 million zero-coupon convertible bonds due in 2026 have been repurchased or redeemed and canceled[18] - The second batch of RMB 1,916 million zero-coupon USD-settled convertible bonds due in 2026 were repurchased or redeemed and delisted in June 2024[18] - The company's subsidiary Pharmaron (Hong Kong) International Limited invested an additional USD 7 million in PharmaGend, holding 35% of its shares[18] - The company increased its investment in AstraZeneca Fund to RMB 191 million, accounting for 8.46% of the fund's total subscribed capital[18] - The company completed the repurchase of shares through centralized bidding on July 26, 2024[19] - The company adjusted the 2021, 2022, and 2023 A-share restricted stock incentive plans on August 28, 2024[19] Operating Costs and Expenses - Total operating costs for the current period are 7,773,877,243.72 yuan, up from 7,354,768,450.44 yuan in the previous period[24] - Research and development expenses for the current period are 332,252,436.76 yuan, up from 296,764,121.85 yuan in the previous period[24]

| 序号 | 股东名称 | 持股数量 | 占公司扣除回购专户 | | --- | --- | --- | --- | | | | （股） | 股份后总股本的比例 | | 1 | 深圳市信中康成投资合伙企业（有限合伙） | 260,827,958 | 14.67% | | 2 | 深圳市信中龙成投资合伙企业（有限合伙） | 44,498,506 | 2.50% | | | 合计 | 305,326,464 | 17.17% | 注：上表合计数与各明细数直接相加之和在尾数上如有差异，是因四舍五入所致。 证券代码：300759 证券简称：康龙化成 公告编号：2024-065 康龙化成（北京）新药技术股份有限公司 关于持股 5%以上股东的一致行动人减持股份的预披露公告 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）及其一致行 动人深圳市信中龙成投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、 准确和完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于近日收到 公司持股 ...

樓柏良博士 （股份代號：3759） 董事會會議通告 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2024年10月29日（星期二）舉行，藉以（其中包括）審議及批 准本公司及其附屬公司截至2024年9月30日止九個月之第三季度業績。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 中華人民共和國，北京 2024年10月15日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事胡柏風先生及李家慶先生；獨立非執行董事周其林先生、李麗華女士、曾 坤鴻先生及余堅先生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 第 1 頁 共 10 頁 v 1.1.0 FF301 呈交日期: 2024年10月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | ...

证券代码：300759 证券简称：康龙化成 康龙化成（北京）新药技术股份有限公司投资者关系活动记录表 编号：2024-05 | --- | --- | --- | |-------------------------|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | □ 特定对象调研 \n□ 媒体采访 \n□ 新闻发布会 √ 现场参观 □ 其他 | □ 分析师会议 \n □ 业绩说明会 \n □ 路演活动 | | 参与单位名称及 人员姓名 | 等 10 余家机构 | 中金公司、招商证券、高毅资产、国泰基金 ...

2023 年 10 月 18 日，康龙化成（北京）新药技术股份有限公司（以下简称 "公司"）召开了第三届董事会第三次会议和第三届监事会第三次会议，分别审 议通过了《关于投资参股境外公司暨关联交易的议案》，同意公司以自有资金 1,050 万美元通过全资子公司 Pharmaron (Hong Kong) International Limited（以下 简称"康龙香港国际"）与合作方 CMS MEDICAL VENTURE PTE. LTD.、Rxilient Health Pte. Ltd.、HEALTHY GOAL LIMITED 共同投资位于新加坡的 Rxilient Biohub Pte. Ltd.（现更名为 PharmaGend Global Medical Services Pte. Ltd.，以下简 称"合资公司"）。关联董事李家庆先生已在董事会上对该议案回避表决，独立董 事对此发表了事前认可意见和同意的独立意见。具体内容详见公司于 2023 年 10 月 19 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于投资参股境外公司暨 关联交易的公告》（公告编号：2023-093）。 20 ...

证券代码：300759 证券简称：康龙化成 公告编号：2024-063 康龙化成（北京）新药技术股份有限公司 2024年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东大会是否出现否决提案的情形：否。 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1．康龙化成（北京）新药技术股份有限公司（以下简称"公司"）2024 年第 一次临时股东大会（以下简称"本次股东大会"）通知公告已于 2024 年 8 月 28 日以公告形式发出。 2．会议召开的时间： （1）现场会议召开时间：2024 年 9 月 13 日（星期五）14:30； （1）2024 年第一次临时股东大会出席情况 | 2024 年第一次临时股东大会： | | | | --- | --- | --- | | 1、出席会议的股东和代理人数 | | 531 | | 其中：A | 股股东人数 | 530 | | 境外上市外资股股东人数（H | 股） | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | | 710,1 ...

北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 2024 年第一次临时股东大会的 法律意见书 致：康龙化成（北京）新药技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》及中国证券监督管理委员会发布的《上市公司股东大会规则》等 规定，北京市中伦律师事务所（以下简称"本所"）接受康龙化成（北京）新药 技术股份有限公司（以下简称"公司"）的委托，指派本所律师对公司 2024 年 第一次临时股东大会（以下简称"本次股东大会"）进行见证并就相关事项出具 本法律意见书。 本法律意见书仅就本次股东大会的召集人资格、召集和召开程序、出席本次 股东大会人员的资格、会议表决程序是否符合法律、法规、规范性文件及《公司 章程》的规定以及表决结果是否合法有效发表意见，而不对本次股东大会所审议 的议案内容以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发 表意见。 2. 提供给本所的文件中所述的全部事实都是真实、准确、完整的； 3. 提供给本所的文件的签署人均具有完全民事行为能力，并且其签署行为 已获得恰当、有效的授权； 4. 所有提供给本所的复印件与原件一致， ...